A detailed history of Schonfeld Strategic Advisors LLC transactions in Novavax Inc stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 18,829 shares of NVAX stock, worth $160,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,829
Previous 22,901 17.78%
Holding current value
$160,234
Previous $289,000 17.99%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.71 - $17.11 $43,611 - $69,671
-4,072 Reduced 17.78%
18,829 $237,000
Q2 2024

Aug 14, 2024

BUY
$3.89 - $20.97 $89,084 - $480,233
22,901 New
22,901 $289,000
Q4 2023

Feb 14, 2024

SELL
$4.8 - $7.67 $352,060 - $562,563
-73,346 Reduced 87.59%
10,395 $49,000
Q3 2023

Nov 14, 2023

BUY
$6.81 - $9.74 $570,276 - $815,637
83,741 New
83,741 $606,000
Q4 2022

Feb 14, 2023

SELL
$8.86 - $25.04 $1.41 Million - $3.98 Million
-158,959 Reduced 78.13%
44,500 $457,000
Q3 2022

Nov 14, 2022

BUY
$18.2 - $76.12 $2.58 Million - $10.8 Million
141,731 Added 229.61%
203,459 $3.7 Million
Q2 2022

Aug 15, 2022

BUY
$36.28 - $75.29 $1.25 Million - $2.6 Million
34,546 Added 127.09%
61,728 $3.17 Million
Q1 2022

May 16, 2022

BUY
$69.73 - $142.9 $1.44 Million - $2.94 Million
20,608 Added 313.48%
27,182 $2 Million
Q4 2021

Feb 14, 2022

BUY
$134.56 - $217.97 $884,597 - $1.43 Million
6,574 New
6,574 $941,000
Q3 2021

Nov 16, 2021

SELL
$177.8 - $270.58 $2.29 Million - $3.49 Million
-12,900 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$121.0 - $257.67 $1.56 Million - $3.32 Million
12,900 New
12,900 $2.74 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $666M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.